A Phase 1 interventional study of VIR-2218 and VIR-3434 in Hepatic Impairment and Cirrhosis, sponsored by Vir Biotechnology, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Vir Biotechnology, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 415 studies in Fibrosis with a site in United States — 81 open to participants now, 109 under way, 13 of them phase 3. Fibrosis · United States.
Among the 415 studies in Fibrosis with a site in United States, this one is the 121st largest by enrollment of the 330 interventional ones that give a count, is one of 18 that started in 2022, is one of 43 in phase 1, and was the 328th registered.
1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.
Browse Fibrosis studies →81 of the 415 studies in Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 50+ · Men only
Medanta, The Medicity, India · Sites in United States, India
Ages 19+
Pulmovant, Inc. · Sites in United States
Ages 18–85
Joseph C. Wu · Sites in United States
Ages 40+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Fibrosis studies recruiting now, 111 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
415 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 117 · Phase 3 59 · Phase 4 25
First in 1977; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 63 across 841 interventional studies indexed under Fibrosis.
Median enrollment 52 across the 330 interventional studies, 95 across the 84 observational. Of the 273 that completed or were terminated, 125 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
126 of 415 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 1 study filed under Fibrosis — fewer than ten, so there is no comparison to draw.
34 of the studies in Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06812390Anahita Rabiee MD MHSAlbumin Assisted Diuresis in Patients with Cirrhosis and Ascites | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 415 studies in Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Participants may be enrolled in Cohorts 1, 2, 3, 4, 5, 6, 7, 8, and 9 in a non-randomized way.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria: Healthy matched participants
Inclusion criteria: Hepatic impaired participants
Exclusion Criteria:
Exclusion criteria: Healthy matched participants
Exclusion criteria: Participants with Hepatic impairment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in Cohort 1 will be receiving VIR-2218 monotherapy.
Drug: VIR-2218
This arm is optional based on Cohort 1. All participants in Cohort 2 will be receiving VIR-2218 monotherapy.
Drug: VIR-2218
This cohort is optional. All participants in Cohort 3 will be receiving VIR-2218 monotherapy.
Drug: VIR-2218
All participants in Cohort 4 will be receiving VIR-3434 monotherapy.
Drug: VIR-3434
All participants in Cohort 5 will be receiving VIR-3434 monotherapy.
Drug: VIR-3434
This arm is optional based on Cohort 5. All participants in Cohort 6 will be receiving VIR-3434 monotherapy.
Drug: VIR-3434
All participants in Cohort 7 will be receiving VIR-3434 and VIR-2218 combination therapy.
Drug: VIR-2218 · Drug: VIR-3434
All participants in Cohort 8 will be receiving VIR-3434 and VIR-2218 combination therapy.
Drug: VIR-2218 · Drug: VIR-3434
This arm is optional based on Cohort 8. All participants in Cohort 9 will be receiving VIR-3434 and VIR-2218 combination therapy.
Drug: VIR-2218 · Drug: VIR-3434
Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218
Time frame: 5 days
Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218
Time frame: 5 days
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218
Time frame: 5 days
Maximum observed Plasma concentration (Cmax) of VIR-3434
Time frame: 18 weeks
Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434
Time frame: 18 weeks
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434
Time frame: 18 weeks
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: Up to 18 Weeks
Incidence of ADA and titers of ADA to VIR-3434 at each study visit for cohorts receiving VIR-3434 therapy
Time frame: 18 Weeks
Ran from Sep 2022 to primary completion in Dec 2025, 38 months.
Of 41 phase 1 interventional studies under Fibrosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 58. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elebsiran · Tobevibart